- Home
- DAC vs EWTX Comparison
DAC vs EWTX Comparison
Compare DAC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAC
- EWTX
- Stock Information
- Founded
- DAC 1972
- EWTX 2017
- Country
- DAC Greece
- EWTX United States
- Employees
- DAC N/A
- EWTX N/A
- Industry
- DAC Marine Transportation
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- DAC Consumer Discretionary
- EWTX Health Care
- Exchange
- DAC Nasdaq
- EWTX Nasdaq
- Market Cap
- DAC 1.6B
- EWTX 1.5B
- IPO Year
- DAC 2006
- EWTX 2021
- Fundamental
- Price
- DAC $87.77
- EWTX $13.03
- Analyst Decision
- DAC Strong Buy
- EWTX Buy
- Analyst Count
- DAC 1
- EWTX 9
- Target Price
- DAC $105.00
- EWTX $39.89
- AVG Volume (30 Days)
- DAC 106.4K
- EWTX 909.8K
- Earning Date
- DAC 08-04-2025
- EWTX 08-07-2025
- Dividend Yield
- DAC 3.87%
- EWTX N/A
- EPS Growth
- DAC N/A
- EWTX N/A
- EPS
- DAC 24.48
- EWTX N/A
- Revenue
- DAC $1,013,968,000.00
- EWTX N/A
- Revenue This Year
- DAC $2.55
- EWTX N/A
- Revenue Next Year
- DAC N/A
- EWTX N/A
- P/E Ratio
- DAC $3.58
- EWTX N/A
- Revenue Growth
- DAC 3.10
- EWTX N/A
- 52 Week Low
- DAC $65.40
- EWTX $10.60
- 52 Week High
- DAC $92.85
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- DAC 54.61
- EWTX 35.20
- Support Level
- DAC $85.37
- EWTX $12.72
- Resistance Level
- DAC $88.80
- EWTX $13.37
- Average True Range (ATR)
- DAC 1.93
- EWTX 0.65
- MACD
- DAC -0.18
- EWTX -0.16
- Stochastic Oscillator
- DAC 43.25
- EWTX 24.22
About DAC Danaos Corporation
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.